DEVELOPMENT OF INTERFERON ANTIBODIES IN THE TREATMENT OF SKIN DISEASES WITH RECOMBINANT INTERFERON-ALPHA 2A AT LOW-DOSES

被引：0
|
作者：
CORBILLET, V
CELERIER, P
LEBON, P
LITOUX, P
DRENO, B
机构：
[1] CHU, DERMATOL CLIN, F-44035 NANTES 01, FRANCE
[2] HOP ST VINCENT DE PAUL, SERV VIROL BACTERIOL & HYG, F-75674 PARIS, FRANCE
来源：
ANNALES DE MEDECINE INTERNE | 1995年 / 146卷 / 06期
关键词：
INTERFERON ANTIBODIES; INTERFERON; MELANOMA CUTANEOUS; T CELL LYMPHOMA;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In this study, we determined the frequency of interferon antibodies in patients with skin diseases treated with low doses of recombinant interferon alpha 2a (1.5 - 18 x 10(6) IU). We essayed serum specimens from 181 patients with malignant melanoma or cutaneous T cell lymphomas (78 patients treated with recombinant interferon alpha 2a and 103 patients in control group) for interferon antibodies before treatment and every 6 months for at least 18 months. Neutralizing interferon alpha 2a antibodies were detected in 27 of 77 treated patients (35%), but none in control group (p < 10(-6)) : 38.2% in melanoma and 12.5% in T cell lymphomas. However antibody formation was not correlated with nonresponse or with frequency of interferon antibodies in patients receiving the combined therapy: interleukin-2 and interferon alpha 2a.
引用
收藏
页码：399 / 403
页数：5
相关论文
共 50 条
  • [1] TREATMENT OF ANGIOBLASTOMA WITH RECOMBINANT INTERFERON-ALPHA(2)
    PARK, KC
    AHN, PS
    LEE, YS
    KIM, KH
    CHO, KH
    [J]. PEDIATRIC DERMATOLOGY, 1995, 12 (02) : 184 - 186
  • [2] TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) WITH LOW-DOSES OF RECOMBINANT INTERFERON-ALPHA-2-B
    DIEDRICH, H
    FREUND, M
    VONWUSSOW, P
    EISERT, R
    METZNER, B
    LINK, H
    WILKE, HJ
    SCHMOLL, HJ
    POLIWODA, H
    [J]. BLUT, 1987, 55 (04): : 280 - 280
  • [3] TREATMENT OF MALIGNANT DISEASES WITH INTERFERON-ALPHA - SOURCES, DOSES, AND FREQUENCY OF TREATMENT
    PORZSOLT, F
    DIGEL, W
    HEIMPEL, H
    [J]. BLUT, 1986, 53 (03): : 229 - 230
  • [4] Response to sequential treatment with lymphoblastoid interferon-alpha in patients with Ph+ chronic myeloid leukemia unresponsive to recombinant interferon-alpha (rIFN alpha 2a) and neutralizing-rIFN alpha 2a antibodies negative
    Russo, D
    Candoni, A
    Grattoni, R
    Minisini, R
    Rosti, G
    [J]. HAEMATOLOGICA, 1997, 82 (03) : 348 - 350
  • [5] Interferon immunogenicity: Technical evaluation of interferon-alpha 2a
    Hochuli, E
    [J]. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1997, 17 : S15 - S21
  • [6] RECOMBINANT INTERFERON-ALPHA THERAPY IN MYELOPROLIFERATIVE DISEASES
    KOS, M
    KORNINGER, C
    LECHNER, K
    NIESSNER, H
    PABINGER, I
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 1987, 99 (05) : 166 - 167
  • [7] Interferon immunogenicity: Preclinical evaluation of interferon-alpha 2a
    Palleroni, AV
    Aglione, A
    Labow, M
    Brunda, MJ
    Pestka, S
    Sinigaglia, F
    Garotta, G
    Alsenz, J
    Braun, A
    [J]. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1997, 17 : S23 - S27
  • [8] Treatment of cirrhotic hepatitis C virus patients with daily doses of interferon-alpha(2a)
    Cooksley, WGE
    Dudley, FJ
    Watson, K
    [J]. JOURNAL OF VIRAL HEPATITIS, 1997, 4 : 75 - 78
  • [9] TREATMENT OF DECOMPENSATED VIRAL-HEPATITIS B-INDUCED CIRRHOSIS WITH LOW-DOSES OF INTERFERON-ALPHA
    NEVENS, F
    GOUBAU, P
    VANEYKEN, P
    DESMYTER, J
    DESMET, V
    FEVERY, J
    [J]. LIVER, 1993, 13 (01): : 15 - 19
  • [10] CLINICAL RELEVANCE OF RECOMBINANT INTERFERON-ALPHA(2A) ANTIBODIES IN PATIENTS WITH HAIRY-CELL LEUKEMIA
    STEIS, RG
    LONGO, DL
    [J]. JOURNAL OF INTERFERON RESEARCH, 1994, 14 (04): : 207 - 209
12345